Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing

Conventional measures such as maximum plasma concentration (C(max)) and area under the concentration versus time curve (AUC) may be insufficient to fully describe the pharmacokinetic (PK) profile of extended-release (ER) formulations. A complementary measure, the half-value duration (HVD), correspon...

Descripción completa

Detalles Bibliográficos
Autores principales: Devarakonda, Krishna, Vandenbossche, Joris, Richarz, Ute
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863398/
https://www.ncbi.nlm.nih.gov/pubmed/24349945
http://dx.doi.org/10.1186/2193-1801-2-625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863398/
https://www.ncbi.nlm.nih.gov/pubmed/24349945
http://dx.doi.org/10.1186/2193-1801-2-625

Ejemplares similares